New Delhi, 21/6 (AO Bureau)The government may reconsider the cost of Covaxin being used in India’s vaccination campaign against the coronavirus. NITI Aayog Member (Health) and Head of National COVID-19 Task Force Dr. VK. Paul indicated this on Monday. He said during an interaction with CNBC TV18, “The central government is paying Bharat Biotech Rs 150 for a single dose of Covaccine, which will be reconsidered.” Along with this, he made it clear that at what price the producer company will give vaccine to the private sector, it is for him to decide.
Significantly, Bharat Biotech had said on June 15 that the supply of anti-Covid-19 vaccine vaccine to the central government at the rate of Rs 150 per dose is not sustainable for a long time. Bharat Biotech is currently supplying COVAXIN at the rate of Rs 150 per dose to the central government, Rs 400 per dose to the state governments and Rs 1,200 per dose to private hospitals.
The company justified the high price of covaxin
The company said in a statement that to compensate for the cost of the vaccine, its high price in the private market is necessary. He said that the price for the private sector is also increasing because of the supply price of the Centre. The company justified the higher rate of COVAXIN compared to other Covid-19 vaccines available to the private sector in India, saying that low-volume procurement, high cost of distribution and retail profits etc. is.